China Resources Double-Crane Gains Approval for Definity in China

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving market approval from the National Medical Products Administration (NMPA) to act as the domestic agent for Definity (perflutren lipid microsphere injection). The contrast agent can now be used to enhance the recognition of the left ventricular endocardial boundary when conventional echocardiography is not clear enough.

Product Profile
Definity, originally developed by US firm Lantheus Medical Imaging Inc., is owned by Lantheus MI Canada Inc. as its marketing authorization holder (MAH) in China. It is the first of its kind to be approved in China. The product was first approved in Canada in 2000 and is currently commercially available in over 10 countries and regions globally. This approval marks a significant expansion of Definity’s market presence in the Asia-Pacific region.

Future Implications
With this approval, China Resources Double-Crane will be able to leverage its domestic distribution network to bring Definity to healthcare providers across China. This move is expected to enhance the availability of advanced echocardiography contrast agents, improving diagnostic capabilities and patient outcomes in cardiovascular imaging.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry